Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGGS34 in Advanced Solid Tumors (Dose Escalation and Expansion, Phase I/II)
CTR20254644Phase 2Active
- Sponsor
- Zelgen
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ZGGS34 in Nonhematologic neoplasms, gastric cancer (GC), pancreatic cancer (PC), colorectal cancer (CRC), sponsored by Zelgen. Started Dec 2025; status: active.
02
Drugs
ZGGS34
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20254644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254644.